Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Down 13.1% in July

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a large drop in short interest in the month of July. As of July 15th, there was short interest totalling 80,800 shares, a drop of 13.1% from the June 30th total of 93,000 shares. Approximately 0.5% of the company’s shares are short sold. Based on an average daily volume of 66,400 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc bought a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Wall Street Analysts Forecast Growth

APTO has been the subject of a number of recent analyst reports. Canaccord Genuity Group decreased their price objective on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, May 16th. StockNews.com initiated coverage on shares of Aptose Biosciences in a research note on Wednesday, July 24th. They set a “hold” rating for the company. Piper Sandler reissued an “overweight” rating and set a $5.00 target price on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research note on Friday, June 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Aptose Biosciences Stock Performance

Shares of Aptose Biosciences stock traded up $0.01 during midday trading on Tuesday, reaching $0.57. 84,307 shares of the company’s stock traded hands, compared to its average volume of 78,634. The company has a market cap of $10.36 million, a price-to-earnings ratio of -0.09 and a beta of 1.27. The company’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $1.35. Aptose Biosciences has a 52 week low of $0.55 and a 52 week high of $5.10.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.09. As a group, equities research analysts predict that Aptose Biosciences will post -2.62 earnings per share for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.